Professional background
Dr Maryam Subhan is a haematology consultant in the haemostasis and thrombosis team at UCLH. She completed her medical training at King’s College London and speciality training at UCLH. She undertook her PhD at UCL investigating risk factors predisposing to immune-mediated Thrombotic Thrombocytopenia Purpura (TTP). As part of the team, she manages patients with TTP and other thrombotic microangiopathies, ITP, venous thromboembolism and bleeding disorders.
Research interests
- Haemostasis and thrombosis
- Thrombotic Thrombocytopenia Purpura (TTP)
Publications
- Arulkumaran N, Thomas M, Stubbs M, Prasannan N, Subhan M, Singh D, Ambler G, Waller A, Singer M, Brealey D, Scully M. A randomised controlled trial of plasma exchange compared to standard of care in the treatment of severe COVID-19 infection (COVIPLEX). Sci Rep. 2024 Jul 23;14(1):16876.
- Prasannan N, Dragunaite B, Subhan MO, Thomas M, de Groot R, Singh D, Vanhoorelbeke K, Scully M. Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated Thrombotic Thrombocytopenic Purpura. Blood. 2024 Mar 19: blood.2023023269.
- Singh, D, Subhan, MO, de Groot, R, Vanhoorelbeke, K, Zadvydaite, A, Dragūnaitė, B, & Scully, M (2023). ADAMTS13 activity testing: evaluation of commercial platforms for diagnosis and monitoring of thrombotic thrombocytopenic purpura. Research and practice in thrombosis and haemostasis, 7(2), 100108.
- Subhan MO, de Groot R, Scully M (2023). Unusually high ADAMTS13 activity in a patient with congenital thrombotic thrombocytopenic purpura. Br J Haematol. 200(5), 673–675.
- HaemSTAR Collaborators. Diagnostic uncertainty presented barriers to the timely management of acute thrombotic thrombocytopenic purpura in the United Kingdom between 2014 and 2019. J Thromb Haemost. 2022 Jun;20(6):1428-1436.
- Shin JS, Subhan MO, Cambridge G, Guo Y, de Groot R, Scully M, Thomas M. Alterations in B- and circulating T-follicular helper cell subsets in immune thrombotic thrombocytopenic purpura. Blood Adv. 2022 Jun 28;6(12):3792-3802.
- Subhan M, Scully M. Advances in the management of TTP. Blood Rev. 2022 Feb 17:100945.
- Wilson AJ, Troy-Barnes E, Subhan M, et al. Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID- 19. Br J Haematol. 2020 Jun 25:10.1111/bjh.16962.